Stock Price Quote

CAPLIN POINT LABORATORIES LTD.

NSE : CAPLIPOINTBSE : 524742ISIN CODE : INE475E01026Industry : Pharmaceuticals & DrugsHouse : Private
BSE1806.00-79.15 (-4.2 %)
PREV CLOSE ( ) 1885.15
OPEN PRICE ( ) 1890.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 14695
TODAY'S LOW / HIGH ( )1800.00 1899.00
52 WK LOW / HIGH ( )1221 2636
NSE1806.70-77.7 (-4.12 %)
PREV CLOSE( ) 1884.40
OPEN PRICE ( ) 1886.00
BID PRICE (QTY) 1806.70 (42)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 113217
TODAY'S LOW / HIGH( ) 1799.00 1900.00
52 WK LOW / HIGH ( )1225 2641
1D 1M 3M 1Y 3Y 5Y
JavaScript chart by amCharts 3.4.2Show all

STOCK SUMMARY

Incorporation Year : 1990
Management Info
C C Paarthipan - Chairman Sridhar Ganesan - Managing Director
Registered Office

Address 3rd Floor, “ Ashvich Towers”,No.3, Developed Plots Industrial Estate,Perungudi,
Chennai,
Tamil Nadu-600096

Phone 044-24968000 / 8012772888 / 71148000

Email info@caplinpoint.net

Website www.caplinpoint.net

Registrars Details
Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
II Floor , Kences Towers,No 1 Ramakrishna Street,North Usman Road, T Nagar,Chennai
Listing : BSE, NSE

NEWS

23Apr Caplin Point Laboratories informs abo
Caplin Point Laboratories has informed that it enclosed a Press Release..
23Apr Caplin Point Laboratories’ arm gets US
Caplin Point Laboratories’ subsidiary -- Caplin Steriles has been grante..
02Apr Caplin Point Laboratories’ arm acquire
Caplin Point Laboratories’ subsidiary -- Caplin Point Far East has acqui..
27Feb Caplin Point’s arm gets USFDA’s final
Caplin Point Laboratories’ subsidiary -- Caplin Steriles has been grante..
05Feb Caplin Point’s arm gets USFDA’s approv
Caplin Point Laboratories’ subsidiary -- Caplin Steriles has been grante..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit747.12837.1
Gross Profit 1001.7 3657.4
Operating Profit 1062.23929.2
Net Sales 1852.36250.9

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

TTK Healthcare (BSE)
peergroup  1233.80 (0.44%)
M.Cap ( in Cr)1743.40
Jagsonpal Pharma (BSE)
peergroup  243.55 (1.82%)
M.Cap ( in Cr)1618.11
Alivus Life Sciences (BSE)
peergroup  1034.35 (0.39%)
M.Cap ( in Cr)12674.62
Oxygenta Pharma (BSE)
peergroup  85.05 (4.70%)
M.Cap ( in Cr)314.54
Bafna Pharma (BSE)
peergroup  79.74 (4.99%)
M.Cap ( in Cr)188.64

Shareholding Pattern

PROMOTERS 70.56%
NON-INSTITUTION 21.7%
MUTUAL FUNDS/UTI 1.74%
FI/BANKS/INSURANCE 0.2%
GOVERNMENT 0%
FII 0%

About Caplin Point Laboratories Ltd.

Caplin Point Laboratories Ltd. was incorporated in the year 1990. Its today's share price is 1806. Its current market capitalisation stands at Rs 13727.71 Cr. In the latest quarter, company has reported Gross Sales of Rs. 6250.9 Cr and Total Income of Rs.7309.3 Cr. The company's management includes G Venkatram, S Deenadhayalan, R Nagendran, CK Gariyali, R Vijayaraghavan, Sridhar Ganesan, C C Paarthipan.

It is listed on the BSE with a BSE Code of 524742 , NSE with an NSE Symbol of CAPLIPOINT and ISIN of INE475E01026. It's Registered office is at 3rd Floor, “ Ashvich Towers”,No.3, Developed Plots Industrial Estate,PerungudiChennai-600096, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Brahmayya & Co, CNGSN & Associates, CNGSN & Associates LLP, M Raghunath & Co

1.NSE exchange is Stopping the facility of Stop-Loss Market (SL-M) orders In option trade from 27th Sept 2021 to avoid freak trades and reduce its impact significantly. 2. Introduction of T+1 rolling settlement on optional basis. Stock Exchange may choose to offer T+1 settlement cycle. There shall be no netting between T+1 and T+2 settlements. Circular provisions come into force with effect from Jan: @SEBI_India 3. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. 4. Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 5. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month. 6.Do not share sensitive information like User ID, Password, OTP, etc., with anyone. Regards, Nirmal Bang.
1.NSE exchange is Stopping the facility of Stop-Loss Market (SL-M) orders In option trade from 27th Sept 2021 to avoid freak trades and reduce its impact significantly. 2. Introduction of T+1 rolling settlement on optional basis. Stock Exchange may choose to offer T+1 settlement cycle. There shall be no netting between T+1 and T+2 settlements. Circular provisions come into force with effect from Jan: @SEBI_India 3. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. 4. Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 5. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month. 6.Do not share sensitive information like User ID, Password, OTP, etc., with anyone. Regards, Nirmal Bang.

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.
Close X
OPEN

DEMAT ACCOUNT

AND START YOUR

INVESTMENT

JOURNEY WITH US
(You will receive a Call & SMS from our end)
Popup-Character

Disclaimer: NIRMAL BANG SECURITIES PVT LTD: Investment in Securities market are subject to market risks. Read all the related documents carefully before investing. Please read the Do’s and Don’ts prescribed by the Commodity Exchange before trading. We do not offer PMS Service for the Commodity segment. Opening of account will not guarantee allotment of shares in IPO. Investors are requested to do their own due diligence before investing in any IPO. The securities quoted are exemplary and are not recommendatory. BSE (Member ID- 498): INB011072759, INF011072759, Exchange Registered Member in CDS; NSE MEMEBR ID- 09391): INB230939139, INF230939139, INE230939139; MSEI Member ID-1067): INB260939138, INF260939138, INE260939139: Single Registration No. INZ000202536, PMS Registration No: INP000002981; Research Analyst Registration No: INH000001766; NSDL/ CDSL: IN-DP-CDSL 37-99; Exchange Member ID: MCX - 56460, NCDEX - 1268, ICEX – 2073. Regd. Office: B-2, 301/302, 3rd Floor, Marathon Innova, Off Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013. Tel: 62738000/01; Fax: 62738010 | *NIRMAL BANG NIVESHALAYA PVT LTD: ARN – 111233, Mutual Fund Distributor. Mutual Fund Investments are subject to market risks. Please read the offer documents carefully before Investing.” Regd. Office: B - 201, Khandelwal House, Poddar Road, Near Poddar Park, Malad (East). Mumbai – 400097. | **NIRMAL BANG INSURANCE BROKING PVT LTD: IRDAI Registration No: 795 and Registration Code For the Insurance Broker: IRDAI/DB889/2021. Insurance is the subject matter of the solicitation. For more details on policy terms, conditions, exclusions, limitations, please refer/read policy brochure carefully before concluding sale.